ReviewEndocrinology and metabolism (Seoul, Korea)2017
Update on Modern Management of Pheochromocytoma and Paraganglioma.
Review in Endocrinology and metabolism (Seoul, Korea), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 149 citations in OpenAlex.
- Global epidemiology of pheochromocytoma: a systematic review and meta-analysis of observational studies.Journal of endocrinological investigation · 2025Pooled it
- Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Pooled it
- Management of para-aortic paraganglioma in a patient with uncontrolled blood pressure-a case report.Journal of surgical case reports · 2026Article
- Article
- Adrenal Incidentaloma: From Silent Diagnosis to Clinical Challenge.Biomedicines · 2025Review
- Article
- Perioperative Management Challenges in Silent Pheochromocytoma: A Case Report and Literature Review.Clinical case reports · 2025Article
- Perioperative Blood Pressure Management Recommendations in Pediatric Pheochromocytoma: A 10-Year Narrative Review.Kidney & blood pressure research · 2025Review
- CLINICAL EVALUATION, DIAGNOSIS AND TREATMENT OF PHEOCHROMOCYTOMA.Acta clinica Croatica · 2024Review
- Atypical Presentation of Pheochromocytoma: A Case Report of Ventricular Tachycardia in a Young Woman.Cureus · 2024Article
- Management of Pheochromocytomas and Paragangliomas.The Surgical clinics of North America · 2024Review
- Inferior Laryngeal Nerve Paraganglioma With Norepinephrine Hypersecretion Diagnosed Shortly After Pregnancy.JCEM case reports · 2024Article
- Evaluating the diagnostic efficacy of whole-body MRI versusScientific reports · 2024Article
- Article
- Management of Abdominal Paraganglioma: A Single Center's Experience.Medicina (Kaunas, Lithuania) · 2024Article
- Article
- A case report on pheochromocytoma mimicking as fulminant myocarditis-a diagnostic challenge.Frontiers in cardiovascular medicine · 2024Article
- Bone metastasis manifested 52 years after resection of an apparently benign paraganglioma: A case report.SAGE open medical case reports · 2024Article
- [Comparison of the effectiveness of various methods for determining the level of metanephrines in the diagnosis of pheochromocytomas].Problemy endokrinologii · 2023Article
- An Overview of Circulating Biomarkers in Neuroendocrine Neoplasms: A Clinical Guide.Diagnostics (Basel, Switzerland) · 2023Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite all technical progress in modern diagnostic methods and treatment modalities of pheochromocytoma/paraganglioma, early consideration of the presence of these tumors remains the pivotal link towards the best possible outcome for patients. A timely diagnosis and proper treatment can prevent the wide variety of potentially catastrophic cardiovascular complications. Modern biochemical testing should include tests that offer the best available diagnostic performance, measurements of metanephrines and 3-methoxytyramine in plasma or urine. To minimize false-positive test results particular attention should be paid to pre-analytical sampling conditions. In addition to anatomical imaging by computed tomography (CT) or magnetic resonance imaging, new promising functional imaging modalities of photon emission tomography/CT using with somatostatin analogues such as ⁶⁸Ga-DOTATATE (⁶⁸Ga-labeled DOTA(0)-Tyr(3)-octreotide) will probably replace ¹²³I-MIBG (iodine-123-metaiodobenzylguanidine) in the near future. As nearly half of all pheochromocytoma patients harbor a mutation in one of the 14 tumor susceptibility genes, genetic testing and counseling should at least be considered in all patients with a proven tumor. Post-surgical annual follow-up of patients by measurements of plasma or urinary metanephrines should last for at least 10 years for timely detection of recurrent or metastatic disease. Patients with a high risk for recurrence or metastatic disease (paraganglioma, young age, multiple or large tumors, genetic background) should be followed up lifelong.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.